Early Phase Oncology CRO
Support for early phase oncology clinical development as studies take shape
Worldwide helps sponsors design and run first-in-human and Phase I/II oncology studies with particular expertise in dose escalation, optimization, and expansion on a global scale. This early phase focus helps move novel oncology therapies into the clinic and toward proof of concept as quickly and safely as possible.
Tell us about your study
We’ll connect you with the right oncology clinical
development team.
Your Early Phase Challenges
Why Early Phase Oncology Needs Different Support
Early phase oncology studies are shaped by scientific uncertainty from the start. Sponsors are working to establish proof of concept, optimize dose, and refine the signal while emerging data continues to influence what the study needs next. That creates pressure around study design, patient access, protocol flexibility, and the speed of critical decisions. Worldwide helps sponsors manage that complexity with specialized early phase oncology expertise, global operational support, and teams equipped to keep pace as studies evolve.
Proof of Concept Depends on Early Decisions
In early phase oncology, study design, dose strategy, and early signals can shape the path of the entire program. Worldwide helps sponsors move forward with support built for dose escalation, optimization, and expansion.
Global Reach Helps Early Studies Move Faster
Early phase oncology programs may need broader patient access sooner than expected. With global reach and a relationship-based early phase site network, Worldwide helps sponsors expand earlier and support enrollment across regions.
Flexible Execution Matters When Studies Evolve
Protocol changes are expected in early phase oncology as data begins to emerge. Worldwide helps sponsors manage cohort changes, amendments, and cross-functional decisions without losing momentum at a critical stage of development.
Early Phase Expertise Helps Teams Act on Data
In early phase oncology, safety, dosing, and efficacy signals need timely review. Worldwide brings oncology expertise across functions and real-time clinical analytics that help sponsors interpret findings and make informed next-step decisions.
Partnership & Approach
A Partner Ready for Early Phase Uncertainty
Early phase oncology often requires teams to make important decisions in real time. Worldwide partners closely with sponsors to help coordinate across functions, maintain momentum through study changes, and keep execution aligned with the goal of reaching proof of concept quickly.
Early Phase Studies
in Past 5 Years
Average Years of
Oncology Experience
Why Worldwide
What Makes Worldwide the Right Early Phase Oncology Fit?
Worldwide brings the early phase oncology expertise, flexibility, and global support sponsors need when studies are still taking shape.
Built for Early Decisions
Worldwide supports sponsors at the earliest stages of clinical development, where safety, dose optimization, and early efficacy signals are still being established. That early phase focus helps teams plan and execute around the decisions that matter most at this point in development.
Active Portfolio
in Phase I/II
Flexible as Studies Evolve
Early phase oncology protocols are often iterative and continue evolving as the study progresses. Worldwide helps sponsors manage adaptive designs, cohort enrollment, protocol amendments, and related adjustments in an environment where emerging data is expected to shape the path forward.
Global Reach When Needed
For many early phase oncology programs, global reach is needed to support timelines and patient access. Worldwide helps sponsors plan for multi-country startup, specialty site access, and broader patient reach while staying focused on early development goals and milestones.
Oncology Expertise Across Functions
Early phase oncology decisions affect more than one part of the study team. Worldwide brings experienced oncology support across all operational functions, helping sponsors connect scientific goals, operational planning, data review, and analysis more effectively.
Support for Emerging Signals
As data begins to flow, sponsors need immediate access to early safety, dosing, and efficacy signals. Worldwide’s early phase model includes real-time clinical analytics and visualizations to simplify safety review committee (SRC) meetings and support interpretation of emerging signals for informed next-step decisions.
Services & Capabilities
Comprehensive Oncology CRO Services
- Protocol Design and Clinical Development Planning
- Regulatory Consulting and Global Submissions
- Global Project Management
- Feasibility Analysis and Site Selection Strategy
- Site Initiation and Study Start-up
- Patient Enrollment
- Dose Escalation, Optimization and Cohort Management
- Site Monitoring and Management
- Data Management
- Clinical Data Analytics and Review
- Clinical Science
- Biostatistics
- Medical Monitoring
- Safety / Pharmacovigilance
- Medical Writing
Study Design & Startup
Worldwide helps sponsors plan and launch early phase oncology studies with attention to study design, dose optimization, country and site strategy, startup timelines, regulatory demands, and execution risks from the beginning.
Dose & Cohort Management
Our teams support Bayesian dose-escalation methods, dose optimization and expansion, cohort management, and protocol amendments in a setting where the study may continue evolving as data emerges.
Site & Patient Strategy
Worldwide helps sponsors identify specialty sites, investigators, and patient-access strategies that support startup and enrollment speed in early phase oncology studies, including programs that require broad geographic reach.
Early Global Execution
For studies that need multi-country execution, Worldwide helps sponsors manage startup, regulatory submissions, specialty-site access, and broader operational complexity without losing focus on early phase needs.
What Our Clients Say
“The Worldwide oncology team is passionate about the success of their client’s projects. They focus on proactive solutions when issues arise and are willing and able to adapt and pivot in almost real-time to the needs of their biopharma customers. They aim to be a true extension of our team and take feedback to heart – making adjustments when needed.”
Small to Mid-Size Oncology Biotech
FAQ & Insights
What Sponsors Need to Know
Early phase oncology is different because this is the first time the drug is being introduced to humans, and despite the best preclinical and translational modeling, important variables and unknowns remain. Sponsors are focused on speed to proof of concept, dose optimization, and signal refinement while emerging data continues to shape the next step. That creates a more iterative and adaptive environment than later stage studies, where the path is often more defined.
Yes. Worldwide supports sponsors across the continuum of early clinical development, from clinical development planning and protocol design through FDA, EMA, and global regulatory agency interactions, submissions, and first-in-human and Phase I/II trials. Our teams are equipped to manage the operational and strategic demands that can shift as early phase oncology development evolves.
Protocol amendments are expected in early phase oncology development. Worldwide’s early phase approach is built for flexibility where new data may affect what the study needs next. Our teams help surface signals early, support go/no-go decisions, respond to emerging data, and coordinate protocol amendments so study momentum is maintained.
With operations in 70+ countries, Worldwide helps sponsors plan a global site, investigator, and patient strategy with the needs of early phase oncology in mind. That includes country and feasibility planning, regulatory consulting, specialty Phase I oncology units that can initiate and enroll quickly, and support for studies that may require broader geographic reach earlier in development.
With over 70% of our active oncology portfolio focused in early phase development, Worldwide is built to bring expertise across all functions, not only at the clinical or leadership level. That matters because safety and data are critical to rapid early phase decisions that can shape the future trajectory of the drug.
Insights
Explore Our Early Phase Oncology Insights
Oncology Expertise
Looking for Other Oncology Specializations?
See what Worldwide Clinical Trials can do for you.
Your study has unique goals, risks, and decisions ahead. Tell us a little about your needs, and our team will connect you with the right Worldwide experts to discuss how our scientific, medical, and operational support can help move your program forward with confidence.
